CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Approximately 23% of NYUCI therapeutic trials are Investigator-Initiated Trials. Accrual to investigator-initiated studies at NYUCI has increased by almost 10% over the last funding period and this category now accounts for 68.6% of all therapeutic accruals. Protocols considered for PSRS funds have to meet the following requirements: 1) Designation of high priority by a NYUCI Disease Management Group and/or CCSG Scientific Research Program; 2) Approval and high merit score by the Protocol Review &Monitoring Committee (PRMC); 3) Clearance provided by the Clinical Trials Office that all other institutional requirements and investigator's conduct of research are met;and 4) Recommendation by the PRMC, Cancer Institute Director and CCIC for funding. The CCIC, in conjunction with the PSRS Chair, review all relevant approvals, scores, and the financial assessment of the trial to make the determination about PSRS funding.

Public Health Relevance

Early phase clinical trials are an essential (and often the last) step in demonstrating that scientific advances originating in the laboratory are applicable to patients. PSRS provides mentorship and other resources for a team of investigators to achieve these goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-34
Application #
8765187
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
34
Fiscal Year
2014
Total Cost
$7,505
Indirect Cost
$3,077
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Litwinoff, Evelyn M S; Gold, Merav Y; Singh, Karan et al. (2018) Myeloid ATG16L1 does not affect adipose tissue inflammation or body mass in mice fed high fat diet. Obes Res Clin Pract 12:174-186
Snetkova, Valentina; Skok, Jane A (2018) Enhancer talk. Epigenomics 10:483-498
Fan, Xiaozhou; Alekseyenko, Alexander V; Wu, Jing et al. (2018) Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67:120-127
Gregory, Ann C; Sullivan, Matthew B; Segal, Leopoldo N et al. (2018) Smoking is associated with quantifiable differences in the human lung DNA virome and metabolome. Respir Res 19:174
Lee, Chul-Hwan; Holder, Marlene; Grau, Daniel et al. (2018) Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2. Mol Cell 70:435-448.e5
Bertrand, Anne; Baron, Maria; Hoang, Dung M et al. (2018) In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI. Methods Mol Biol 1779:527-541
Taylor, Martin S; Altukhov, Ilya; Molloy, Kelly R et al. (2018) Dissection of affinity captured LINE-1 macromolecular complexes. Elife 7:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Jung, Seungyoun; Allen, Naomi; Arslan, Alan A et al. (2018) Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 142:262-270
Gong, Yixiao; Lazaris, Charalampos; Sakellaropoulos, Theodore et al. (2018) Stratification of TAD boundaries reveals preferential insulation of super-enhancers by strong boundaries. Nat Commun 9:542

Showing the most recent 10 out of 1170 publications